Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients
Clinical Transplantation · 2023-02 · 37 (2)
DOI: 10.1111/ctr.14897 ↗At a glance
Journal article in Clinical Transplantation, published online on 2023-01-11. Written by Eric D Rubido and 3 co-authors. Institution: Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Anticoagulants, Atrial Fibrillation. Cited 6 times so far (Crossref); 33 references.
Abstract (original language)
Background
Direct oral anticoagulants (DOACs) are widely utilized following cardiothoracic transplantation with limited guidance regarding drug–drug interactions (DDIs), periprocedural management, and DOAC‐specific monitoring.
Methods
We performed a single‐center, retrospective, descriptive analysis of adult cardiothoracic transplant recipients initiated on DOAC therapy between May 2016 and July 2021. The primary endpoint for this analysis was the percentage of patients dosed per package labeling. Secondary endpoints included DOAC prescribing in the context of DDIs, renal dysfunction, and periprocedural management, as well as thromboembolism and major bleeding at 12 months.
Results
A total of 125 patients were included in this analysis with a median age of 62 years. At initiation, 63.2% of patients were dosed according to package labeling. The most common reason for non‐labeled dosing was concomitant azole antifungal therapy. DOAC therapy was held for 82 procedures with no reported thrombotic events and one major bleed in the setting of AKI. Hemodialysis‐dependence was associated with a reduced risk of thrombosis (0 vs. 10 events per 100 PY, p = .002) and an increased risk of major bleeding (23 vs. 8 events per 100 PY, p = .006). Additionally, DOAC‐specific anti‐xa guided dosing was associated with a reduced risk of major bleeding (0 vs. 13 events per 100 PY, p < .001).
Conclusion
Our findings show that deviation from package labeling is common following cardiothoracic transplantation and its association with clinical outcomes warrants further study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
ORCID profiles: Eric D Rubido, Megan H Cooper, Jill Krisl
Cite
APA
Rubido, E. D., Cooper, M. H., Donahue, K. R., & Krisl, J. (2023). Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients. Clinical Transplantation, 37(2). https://doi.org/10.1111/ctr.14897
Vancouver
Rubido ED, Cooper MH, Donahue KR, Krisl J. Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients. Clinical Transplantation. 2023;37(2). doi:10.1111/ctr.14897
BibTeX
@article{Rubido2023,
author = {Rubido, Eric D and Cooper, Megan H and Donahue, Kevin R and Krisl, Jill},
title = {Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients},
journal = {Clinical Transplantation},
year = {2023},
volume = {37},
number = {2},
doi = {10.1111/ctr.14897}
}
EUVIMED